Featured Research

from universities, journals, and other organizations

Refugees and internally displaced persons should have equitable access to HIV treatment

Date:
June 10, 2014
Source:
PLOS
Summary:
In a new article, researchers argue that available evidence suggests that refugees and internally displaced persons in stable settings can sustain high levels of adherence to antiretroviral therapy and viral suppression and should have the same level of access to HIV treatment and support as host nationals.

"Given recent evidence and the moral, legal, and public health arguments, refugees and internally displaced persons situated in stable settings should have equitable access to HIV treatment and supportive services," argue experts from the London School of Hygiene & Tropical Medicine and the United Nations High Commissioner for Refugees, writing in this week's PLOS Medicine.

Joshua Mendelsohn and colleagues argue that available evidence suggests that refugees and internally displaced persons in stable settings can sustain high levels of adherence to antiretroviral therapy and viral suppression and should have the same level of access to HIV treatment and support as host nationals.

The authors make 17 recommendations, including that HIV treatment should be offered to all refugees and internally displaced persons who meet national guidelines, routine adherence monitoring systems should be set up, and point-of-care laboratory monitoring should be implemented wherever feasible.

Joshua Mendelsohn from the London School of Hygiene & Tropical Medicine said: Few would rationally argue that challenges to provision of life-saving treatment should be addressed by denying access."

They continue: "Since antiretroviral therapy can help prevent transmission of HIV to sexual partners, it is in the enlightened self-interest of governments that host refugees and internally displaced persons to support programs that serve all populations within their borders to the highest possible standard."


Story Source:

The above story is based on materials provided by PLOS. Note: Materials may be edited for content and length.


Journal Reference:

  1. Joshua B Mendelsohn, Paul Spiegel, Marian Schilperoord, Nadine Cornier, David A. Ross. Antiretroviral Therapy for Refugees and Internally Displaced Persons: A Call for Equity. PLoS Medicine, 2014; 11 (6): e1001643 DOI: 10.1371/journal.pmed.1001643

Cite This Page:

PLOS. "Refugees and internally displaced persons should have equitable access to HIV treatment." ScienceDaily. ScienceDaily, 10 June 2014. <www.sciencedaily.com/releases/2014/06/140610205407.htm>.
PLOS. (2014, June 10). Refugees and internally displaced persons should have equitable access to HIV treatment. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/06/140610205407.htm
PLOS. "Refugees and internally displaced persons should have equitable access to HIV treatment." ScienceDaily. www.sciencedaily.com/releases/2014/06/140610205407.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins